- In July 2024, Memorial Sloan Kettering Cancer Center (MSKCC) expanded its personalized approach to salivary gland cancer treatment by emphasizing precision medicine, including surgery, radiation, and systemic therapies tailored to tumor type and stage. With multidisciplinary care teams and advanced diagnostic tools, MSKCC continues to lead in delivering individualized treatment strategies aimed at improving patient outcomes for both early-stage and metastatic salivary gland cancers
- In July 2024, findings published in ESMO Open revealed significant advancements in biomarker-driven therapies for recurrent and metastatic salivary gland cancers. The study emphasized the importance of genomic profiling in identifying actionable mutations and optimizing therapy selection. These insights are expected to guide clinical decision-making and enhance the effectiveness of targeted treatment regimens
- In July 2024, during the ESMO Congress 2024, new clinical data were presented supporting the integration of personalized medicine into the treatment of recurrent and metastatic salivary gland cancers. The results suggest that incorporating genetic and molecular markers can significantly improve therapeutic outcomes and pave the way for more effective and patient-specific treatment plans in rare head and neck tumors
